Core Insights - Johnson & Johnson's MedTech segment achieved a 5.4% year-over-year growth in operational sales, reaching approximately $33.8 billion in 2025 [1] - The Innovative Medicine segment also saw growth, with operational sales increasing by 5.3% to about $60.4 billion [2] - The company anticipates overall worldwide operational sales growth of 5.7% to 6.2%, potentially exceeding the $100 billion milestone [6] MedTech Segment Performance - The growth in the MedTech segment was primarily driven by electrophysiology products, Abiomed in the Cardiovascular area, and wound closure products in General Surgery [4] - Abiomed reported an operational growth of 18% in Q4, while Shockwave achieved a 23% growth [4] - Johnson & Johnson completed the acquisition of Shockwave in May 2024, which is expected to enhance the technology's annual sales to at least $1 billion [5] Future Outlook - Both the Shockwave and Carvykti platforms surpassed $1 billion in annual sales for the first time, increasing the total number of platforms generating at least that much revenue to 28 [6] - The company is positioned to become the only healthcare company generating over $100 billion in revenue, supported by its diverse strengths in both Innovative Medicine and MedTech [7]

Core Insights - Johnson & Johnson's MedTech segment achieved a 5.4% year-over-year growth in operational sales, reaching approximately $33.8 billion in 2025 [1] - The Innovative Medicine segment also saw growth, with a 5.3% increase in operational sales, totaling around $60.4 billion [2] - The company anticipates overall worldwide operational sales growth of 5.7% to 6.2%, potentially exceeding the $100 billion mark [6] MedTech Segment Performance - The growth in the MedTech segment was primarily driven by electrophysiology products, Abiomed in the Cardiovascular area, and wound closure products in General Surgery [4] - Abiomed reported an operational growth of 18% in Q4, while Shockwave achieved a 23% growth [4] - Johnson & Johnson completed the acquisition of Shockwave in May 2024, which is expected to enhance annual sales to at least $1 billion [5] Future Outlook - Both the Shockwave and Carvykti platforms surpassed $1 billion in annual sales for the first time, increasing the total number of platforms generating at least that much revenue to 28 [6] - The company is positioned to become the only healthcare company with over $100 billion in revenue, attributed to its diverse strengths in both Innovative Medicine and MedTech [7]

Core Insights - Johnson & Johnson (JNJ) reported a revenue of $24.56 billion for the quarter ended December 2025, marking a year-over-year increase of 9.1% and exceeding the Zacks Consensus Estimate of $24.12 billion by 1.84% [1] - The company's earnings per share (EPS) for the same period was $2.46, up from $2.04 a year ago, also surpassing the consensus EPS estimate of $2.43 by 1.05% [1] Financial Performance Metrics - Organic Sales Growth was reported at 7.1%, exceeding the average estimate of 6.1% from four analysts [4] - Sales in Innovative Medicine for Oncology (CARVYKTI) reached $555 million, compared to the estimated $624.42 million, reflecting a significant year-over-year increase of 66.2% [4] - Sales in Innovative Medicine for Neuroscience (SPRAVATO) were $503 million, surpassing the average estimate of $463.39 million, with a year-over-year growth of 69.4% [4] - International sales totaled $10.37 billion, exceeding the average estimate of $10.14 billion, representing an 11.3% year-over-year increase [4] - MedTech sales in Cardiovascular (Electrophysiology) were $1.43 billion, slightly below the average estimate of $1.48 billion, with a year-over-year change of 7.9% [4] - Total sales in Innovative Medicine reached $15.76 billion, above the five-analyst average estimate of $15.42 billion, indicating a year-over-year growth of 10% [4] - Sales for Innovative Medicine in Oncology (IMBRUVICA) were $684 million, slightly above the estimated $669.55 million, but reflecting a decline of 6.4% year-over-year [4] - MedTech sales in Orthopaedics (Trauma) were $813 million, exceeding the average estimate of $795.14 million, with a year-over-year increase of 6.4% [4] - MedTech sales in Orthopaedics (Spine, Sports & Other) reached $756 million, above the estimated $735.66 million, showing a year-over-year growth of 2.9% [4] - Advanced Surgery sales were $1.18 billion, slightly below the average estimate of $1.19 billion, with a year-over-year increase of 2.1% [4] - Sales in Innovative Medicine for Cardiovascular/Metabolism/Other were $249 million, below the average estimate of $266.45 million, reflecting a year-over-year decline of 11.4% [4] - Sales in Innovative Medicine for Pulmonary Hypertension were $1.18 billion, exceeding the average estimate of $1.12 billion, with a year-over-year growth of 8.4% [4] Stock Performance - Johnson & Johnson's shares have returned +6% over the past month, outperforming the Zacks S&P 500 composite, which saw a change of -0.4% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

分组1 - Johnson & Johnson reported quarterly earnings of $2.46 per share, exceeding the Zacks Consensus Estimate of $2.43 per share, and showing an increase from $2.04 per share a year ago, representing an earnings surprise of +1.05% [1] - The company achieved revenues of $24.56 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.84%, and up from $22.52 billion year-over-year [2] - Johnson & Johnson has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] 分组2 - The stock has increased approximately 5.4% since the beginning of the year, while the S&P 500 has declined by 0.7% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is $2.75 on revenues of $23.05 billion, and for the current fiscal year, it is $11.46 on revenues of $98.46 billion [7] 分组3 - The Zacks Industry Rank indicates that the Large Cap Pharmaceuticals sector is in the top 41% of over 250 Zacks industries, suggesting a favorable outlook for stocks in this category [8] - Eli Lilly, another company in the same industry, is expected to report quarterly earnings of $7.50 per share, reflecting a year-over-year increase of +41%, with revenues projected at $18.21 billion, up 34.6% from the previous year [9]

Core Viewpoint - Johnson & Johnson has provided a sales and profit guidance for the current year that surpasses Wall Street expectations, despite anticipating a significant financial impact from a recent drug pricing agreement with the U.S. government [1][3]. Group 1: Financial Guidance - The company expects current-year sales to be between $100 billion and $101 billion, exceeding consensus estimates of $98.88 billion [4]. - Full-year earnings are projected to be between $11.43 and $11.63 per share, compared to expectations of $11.45 [4]. Group 2: Recent Developments - Johnson & Johnson agreed to lower drug prices for U.S. consumers in exchange for exemptions from broad tariffs, aligning with actions taken by other major pharmaceutical companies [2]. - This initiative is part of broader efforts by the U.S. government to reduce drug costs, particularly in the lead-up to the midterm elections [2]. Group 3: Financial Performance - For the fourth quarter, the company reported revenue of $24.56 billion, reflecting a year-over-year increase of 9.1% and surpassing projections of $24.15 billion [4]. - The strong performance was driven by high demand for medical technology products and a 27% increase in sales of the Darzalex blood cancer treatment [4]. Group 4: Earnings Performance - Adjusted earnings per share reached $2.46, exceeding analyst estimates of $2.04, despite a decline in sales of the psoriasis drug Stelara due to rising biosimilar competition [5].

Group 1 - The fourth quarter earnings season is gaining momentum, with major financial institutions like Charles Schwab and regional banks such as Fifth Third set to report results, alongside Netflix and Intel, which are expected to be focal points [1][5] - An optimistic consensus is emerging, with 7% of S&P 500 companies having reported fourth quarter results as of January 16, and analysts projecting an 8.2% increase in earnings per share for the quarter, marking the 10th consecutive quarter of annual earnings growth for the index [2] - Analysts had initially anticipated an 8.3% increase in earnings per share heading into the reporting period, a decrease from the previous quarter's 13.6% growth rate, but expectations have been raised recently, particularly for technology companies [3] Group 2 - The current earnings season is expected to test the improved stock market breadth observed at the beginning of 2026, with ongoing themes from 2025, such as artificial intelligence and economic policies, continuing to influence market dynamics [4] - This week's earnings releases will also include reports from notable companies such as United Airlines, 3M Company, D.R. Horton, Johnson & Johnson, GE Aerospace, Procter & Gamble, Abbott Laboratories, and Capital One [5]

Core Insights - Johnson & Johnson (JNJ) reported earnings per share of $2.46, exceeding estimates of $2.43, and revenue of approximately $24.56 billion, surpassing the estimated $24.16 billion [1][5] Group 1: Financial Performance - The company's revenue increased by 9% during the fourth quarter, driven primarily by its cancer and autoimmune drug segments [2][5] - JNJ is positioned to potentially reach $100 billion in revenue next year as part of a new strategic initiative [2] - Despite a drug pricing deal with the Trump administration expected to impact profits by "hundreds of millions of dollars," JNJ remains optimistic about its 2026 sales and profit projections [2] Group 2: Financial Metrics - JNJ has a price-to-earnings (P/E) ratio of approximately 21.10, indicating the price investors are willing to pay for each dollar of earnings [3][5] - The price-to-sales ratio is about 5.71, reflecting the value placed on each dollar of sales [3][5] - The enterprise value to sales ratio stands at around 6.00, suggesting the company's total valuation relative to its sales [3] - The enterprise value to operating cash flow ratio is approximately 22.86, showing how the company's valuation compares to its cash flow from operations [4] - JNJ has an earnings yield of about 4.74%, providing a return on investment for shareholders [4] - The company's debt-to-equity ratio is approximately 0.58, indicating a moderate level of debt relative to equity [4] - A current ratio of around 1.07 suggests JNJ's ability to cover short-term liabilities with short-term assets [4]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Market Overview - After a sharp sell-off on Tuesday due to fears of potential U.S. tariffs on Europe, Wall Street attempted a cautious rebound on Wednesday [1] - The Dow Jones Industrial Average rose about 0.6%, outperforming both the S&P 500 and the Nasdaq 100, as investors remained defensive amid geopolitical uncertainty [3] Sector Performance - The oil and gas sector significantly outperformed the broader market, with U.S. natural gas futures at the Henry Hub facility jumping nearly 24%, marking the largest two-day percentage gain on record [4] - Shares of EQT Corp climbed 6%, while Antero Resources Corporation advanced 5% due to weather-related concerns [5] - Crude oil prices remained stable, with WTI settling flat at $60 a barrel [5] Earnings Reports - Netflix Inc. fell more than 4% despite beating quarterly estimates, as its first-quarter 2026 guidance disappointed investors [6] - United Airlines Holdings Inc. rose 2% after exceeding expectations [6] - Johnson & Johnson and Charles Schwab Corporation traded flat after largely meeting forecasts, while Truist Financial Corporation gained 2.8% on upbeat guidance [7] Commodity and Crypto Markets - Gold prices extended their record-breaking run, pushing above $4,850 an ounce, climbing more than 10% year to date [7] - Bitcoin fell for a seventh straight session, dropping toward $88,000, marking its worst losing streak since May 2023 [8] Major Indices Performance - The Dow Jones closed at 48,777.55, up 0.6% [9] - The S&P 500 closed at 6,831.24, up 0.5% [9] - The Nasdaq 100 closed at 25,091.90, up 0.4% [9] Top Gainers and Losers - Lucid Group, Inc. was the top gainer, rising 14.51% [11] - Moderna, Inc. and Intel Corporation also saw significant gains of 11.18% and 8.66% respectively [11] - AST SpaceMobile, Inc. was the top loser, falling 11.42% [12]

Market Overview - Stocks rose following President Trump's address at the World Economic Forum, easing investor concerns regarding U.S. military actions related to Greenland [1] - The rally was noted to be led by "the wrong tech," particularly Micron, which is affected by the current DRAM chip shortage driving prices higher [1] Company Insights - Advanced Micro Devices (AMD) shares increased nearly 9% to approximately $252 per share; however, caution is advised against chasing the rally [1] - Johnson & Johnson is considered a buy after its latest earnings report guidance exceeded Street estimates, despite a recent decline in stock price [1] Upcoming Earnings - Procter & Gamble is set to report earnings, with prior warnings of sharp sales drops in October and November; focus will be on December's numbers and management's outlook [1] Additional Stocks Mentioned - Stocks discussed include Netflix, United Airlines, Johnson & Johnson, Halliburton, and Kraft Heinz, with the CNBC Investing Club holding positions in PG, GOOG, NKE, and NVDA [1]